ENCEPUR should not be used in people who are known to be hypersensitive to the active substance, to any of the excipients or to any residues from manufacture such as formaldehyde, chlorotetracycline, gentamicin, neomycin, egg and chicken proteins.
 
People with acute illnesses requiring treatment should be vaccinated at the earliest 2 weeks after recovery.
 
Vaccination with a complication is a contraindication to repeated vaccination with the same vaccine until the cause is clarified.

Particular caution should be exercised vaccinating patients with pre-existing severe neurological conditions. The safe use of ENCEPUR cannot be proven for people who are sensitive to latex. Under no circumstances should the vaccine be injected intravascularly. Unintentional intravascular administration may provoke reactions, with shock in extreme cases. 

Please consult the SmPC for complete details. As is the case for all vaccines in general it is possible that not all vaccinated individuals will develop protective immunity against TBE.

In normal cases there is no increased risk in vaccination with Encepur for subjects classified with “allergy to chicken protein” based solely on a questionnaire or positive prick test. Vaccination with Encepur normally entails no increased risk for such individuals.